Epigallocatechingallate (EGCG) in Cardiac AL Amyloidosis (EpiCardiAL)

Clinical Trial ID NCT01511263

Rank	Title	Journal	Year	PubWeight™‹?›
1	Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis.	J Clin Oncol	2004	3.43
2	Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis.	Circulation	2003	1.93
3	The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis.	Blood	2010	1.27
4	Amyloidosis: is a cure possible?	Ann Oncol	2008	1.11
5	A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis.	Blood	2014	1.05
6	Epigallocathechin-3-gallate in AL amyloidosis: a new therapeutic option?	Blood	2007	0.97
7	Effects of the main green tea polyphenol epigallocatechin-3-gallate on cardiac involvement in patients with AL amyloidosis.	Clin Res Cardiol	2010	0.92
8	Functional Amyloid Signaling via the Inflammasome, Necrosome, and Signalosome: New Therapeutic Targets in Heart Failure.	Front Cardiovasc Med	2015	0.79
9	Therapy effects of green tea in a patient with systemic light-chain amyloidosis.	Clin Res Cardiol	2008	0.77